Lowest Price Guaranteed From USD 4,499
The cancer biomarker market is estimated to be worth $868 million in 2030 and is expected to grow at CAGR of over 18.3% during the forecast period. Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; these include a variety of targeted therapies, immunotherapies and certain anti-cancer vaccines as well. However, clinical cancer research is still plagued by high failure rates, various drug / therapy-related limitations, and treatment-based adverse effects, some of which have proven to be fatal. A prominent concern is associated with deciding the type of treatment option to be used for a specific cancer. Patients suffering from a singular type of cancer, who may be at the same stage of the disease, have been demonstrated to exhibit different molecular profiles, and thereby, may respond differently to recommended drug / therapy types. In order to address this concern, pharmaceutical developers and healthcare professionals have adopted a more personalized approach to disease diagnosis and treatment. Over time, several molecular markers have been identified and characterized, and many have been validated for use in making important treatment-related decisions.
The role of single analyte biomarkers, such as PD-L1, BRAF, and EGFR, has been well-established across multiple cancer indications. However, due to subtle differences in genomic makeup of individual patients, these biomarkers alone have been shown to be insufficient in determining how patients are likely to respond to various drug / therapy types. Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers, based on genome / exome profiles. Novel biomarkers in cancer, such as tumor mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumor infiltrating lymphocytes (TILs) and certain others, are presently being investigated across numerous clinical studies. Presently, several diagnostics-focused companies have developed / are developing analytical tests for these biomarkers, which are intended to assist physicians in making personalized treatment-related decisions. It is worth highlighting that many big pharmaceutical players have demonstrated interest in cancer biomarker market and have launched clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.
Several recent developments have taken place in the field of cancer biomarker market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Examples of key companies engaged in cancer biomarker market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Dr Lal PathLabs, Foundation Medicine, NeoGenomics Laboratories, Novogene, Q2 Solutions, Personal Genome Diagnostics and Shenzhen Yuce Biotechnology. This market report includes an easily searchable excel database of all the companies providing cancer biomarkers testing, worldwide.
The ‘Cancer Biomarker Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cancer biomarker market. It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in cancer biomarker market.
Amongst various elements, the market research report includes:
The key objective of cancer biomarker market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cancer biomarker market during the forecast period. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the forecast period 2019-2030. In addition, we have provided the likely distribution of the future opportunity based on [A] biomarker (MSI / MMR, TILs, TMB), [B] disease indications (blood cancer, blood cancer, colon cancer, colorectal cancer, lung cancer, melanoma, prostate cancer and others), [C] analytical technique used (immunohistochemistry, next generation sequencing, polymerase chain reaction and others), [D] application area (research use, clinical use, commercial use), and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.
The opinions and insights presented in this market research report were also influenced by discussions conducted with stakeholders in cancer biomarker market. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market report are in USD, unless otherwise specified.